A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 04 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ixazomib (Primary) ; Dexamethasone; Lenalidomide
Indications Multiple myeloma
Focus Therapeutic Use

Most Recent Events

01 Oct 2024 Planned End Date changed from 31 Aug 2024 to 31 Aug 2025.
06 Nov 2019 Results evaluating the safety and efficacy of using lenalidomide and ixazomib as part of consolidation and maintenance therapies after ASCT presented at the 61st Annual Meeting and Exposition of the American Society of Hematology
19 Sep 2019 Planned primary completion date changed from 30 Nov 2019 to 1 Feb 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight